Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Patient Direct | 2,057.1 | 959.7 | 817.7 | | | | | |
| Products & Healthcare Services | 7,898.4 | 8,825.6 | 7,662.4 | | | | | |
| Global Solutions | | | | 8,243.9 | 8,767.5 | | | |
| Global Products | | | | 1,434.0 | 1,111.3 | | | |
| Total revenues | 9,955.5 | 9,785.3 | 8,480.2 | 9,210.9 | 9,418.2 | 9,318.3 | 9,723.4 | 9,772.9 |
| Revenue growth [+] | 1.7% | 15.4% | -7.9% | -2.2% | 1.1% | -4.2% | -0.5% | 3.5% |
| Patient Direct | 114.4% | 17.4% | | | | | | |
| Products & Healthcare Services | -10.5% | 15.2% | | | | | | |
| Global Solutions | | | | -6.0% | | | | |
| Global Products | | | | 29.0% | | | | |
| International | -19.7% | 53.0% | 3.1% | 116.1% | | | | -22.6% |
| Cost of goods sold | 8,129.1 | 8,272.1 | 7,199.3 | 8,082.4 | 8,347.7 | 8,146.4 | 8,536.1 | 8,558.4 |
| Gross profit | 1,826.4 | 1,513.2 | 1,280.8 | 1,128.5 | 1,070.5 | 1,171.9 | 1,187.3 | 1,214.6 |
| Gross margin | 18.3% | 15.5% | 15.1% | 12.3% | 11.4% | 12.6% | 12.2% | 12.4% |
| Selling, general and administrative | 1,633.7 | 1,116.9 | 1,041.3 | 1,023.1 | 952.9 | 1,017.0 | 970.4 | 993.8 |
| Other operating expenses | 49.8 | 16.7 | 24.8 | 32.3 | -383.6 | 39.5 | 5.4 | 3.0 |
| EBITDA [+] | 371.6 | 470.3 | 308.1 | 189.8 | 603.1 | 174.8 | 266.9 | 283.7 |
| EBITDA growth | -21.0% | 52.7% | 62.3% | -68.5% | 245.1% | -34.5% | -5.9% | 6.8% |
| EBITDA margin | 3.7% | 4.8% | 3.6% | 2.1% | 6.4% | 1.9% | 2.7% | 2.9% |
| Depreciation | 149.9 | 50.8 | 51.8 | 72.7 | 66.8 | 43.0 | 45.4 | 56.2 |
| EBITA | 221.7 | 419.5 | 256.2 | 117.2 | 536.3 | 131.8 | 221.5 | 227.6 |
| EBITA margin | 2.2% | 4.3% | 3.0% | 1.3% | 5.7% | 1.4% | 2.3% | 2.3% |
| Amortization of intangibles | 78.8 | 39.8 | 41.5 | 44.0 | 35.1 | 16.4 | 10.0 | 9.8 |
| EBIT [+] | 142.9 | 379.7 | 214.7 | 73.2 | 501.2 | 115.4 | 211.5 | 217.8 |
| EBIT growth | -62.4% | 76.8% | 193.5% | -85.4% | 334.5% | -45.5% | -2.9% | 7.7% |
| EBIT margin | 1.4% | 3.9% | 2.5% | 0.8% | 5.3% | 1.2% | 2.2% | 2.2% |
| Non-recurring items [+] | | 11.2 | 10.6 | | 853.6 | 26.1 | 11.9 | 17.4 |
| Asset impairment | | | | | 853.6 | | | |
| Interest expense | 128.9 | 48.1 | 83.4 | 98.1 | 71.0 | 31.8 | 27.1 | 27.7 |
| Interest expense | 128.9 | 48.1 | 83.4 | 98.1 | 71.0 | 31.8 | 27.1 | 27.7 |
| Other income (expense), net [+] | -3.1 | -43.6 | -10.8 | -3.8 | -3.8 | | | 0.6 |
| Gain (loss) on debt retirement | | -40.4 | -11.2 | -0.8 | | | | |
| Pre-tax income | 10.9 | 276.8 | 109.9 | -28.7 | -427.1 | 57.5 | 172.5 | 173.2 |
| Income taxes | -11.5 | 55.2 | 21.8 | -6.1 | -32.4 | -15.3 | 63.8 | 69.8 |
| Tax rate | | 19.9% | 19.9% | 21.4% | 7.6% | | 37.0% | 40.3% |
| Earnings from continuing ops | 22.4 | 221.6 | 88.1 | -22.6 | -394.7 | 72.8 | 108.8 | 103.4 |
| Earnings from discontinued ops | 0.0 | 0.0 | 0.0 | 0.0 | | | | |
| Net income | 22.4 | 221.6 | 29.9 | -62.4 | -437.0 | 72.8 | 108.8 | 103.4 |
| Net margin | 0.2% | 2.3% | 0.4% | -0.7% | -4.6% | 0.8% | 1.1% | 1.1% |
| |
| Basic EPS [+] | $0.30 | $3.05 | $1.39 | ($0.37) | ($6.58) | $1.21 | $1.78 | $1.66 |
| Growth | -90.1% | 119.2% | -472.8% | -94.3% | -642.1% | -31.9% | 7.0% | 55.8% |
| Diluted EPS [+] | $0.29 | $2.94 | $1.39 | ($0.37) | ($6.58) | $1.21 | $1.78 | $1.66 |
| Growth | -90.0% | 111.7% | -471.9% | -94.3% | -642.1% | -31.9% | 7.0% | 55.8% |
| |
| Dividends per share [+] | | $0.01 | $0.01 | $0.01 | $0.86 | $1.03 | $1.02 | $1.01 |
| Growth | -100.0% | 0.0% | 0.0% | -98.8% | -16.5% | 1.0% | 1.0% | 1.0% |
| |
| Shares outstanding (basic) [+] | 74.5 | 72.7 | 63.4 | 60.6 | 60.0 | 60.0 | 61.1 | 62.1 |
| Growth | 2.4% | 14.8% | 4.6% | 0.9% | 0.0% | -1.8% | -1.6% | -0.2% |
| Shares outstanding (diluted) [+] | 76.2 | 75.5 | 63.5 | 60.6 | 60.0 | 60.0 | 61.1 | 62.1 |
| Growth | 1.0% | 18.9% | 4.9% | 0.9% | 0.0% | -1.8% | -1.6% | -0.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|